cenersen

DRUG3 trials

Sponsors

Eleos, Inc.

Conditions

Acute Myelogenous LeukemiaMyelodysplastic Syndromes

Phase 1

A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)

TerminatedNCT02243124

Eleos, Inc.Myelodysplastic Syndromes

Start: 2014-09-30End: 2015-12-31Updated: 2021-02-21

Phase 2

Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML

CompletedNCT00074737

Eleos, Inc.Acute Myelogenous Leukemia

Start: 2004-04-30End: 2007-05-31Updated: 2014-09-18

Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course

WithdrawnNCT00967512

Eleos, Inc.Acute Myelogenous Leukemia

Start: 2012-01-31End: 2012-01-31Updated: 2014-09-18